Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 21:13:20406223221098136.
doi: 10.1177/20406223221098136. eCollection 2022.

New drugs in cystic fibrosis: what has changed in the last decade?

Juliana Roda  1 , Catarina Pinto-Silva  2 , Iris A I Silva  3 , Carla Maia  2 , Susana Almeida  2 , Ricardo Ferreira  2 , Guiomar Oliveira  4
Affiliations
Review

New drugs in cystic fibrosis: what has changed in the last decade?

Juliana Roda et al. Ther Adv Chronic Dis. .

Abstract

Cystic fibrosis (CF), a life-limiting chronic disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene, affects more than 90,000 people worldwide. Until recently, the only available treatments were directed to symptom control, but they failed to change the course of the disease. New drugs developed in the last decade have the potential to change the expression, function, and stability of CFTR protein, targeting the basic molecular defect. The authors seek to provide an update on the new drugs, with a special focus on the most promising clinical trials that have been carried out to date. These newly approved drugs that target specific CFTR mutations are mainly divided into two main groups of CFTR modulators: potentiators and correctors. New therapies have opened the door for potentially disease-modifying, personalized treatments for patients with CF.

Keywords: CFTR modulators; Cystic fibrosis transmembrane conductance regulator; correctors; potentiator.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Site and mechanism of action of different CFTR modulator drugs. Source: Reused with permission from De Boeck.
See this image and copyright information in PMC

References

    1. Stephenson AL, Stanojevic S, Sykes J, et al.. The changing epidemiology and demography of cystic fibrosis. Presse Med 2017; 46: e87–e95. - PubMed
    1. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891–1904. - PubMed
    1. Fajac I, De Boeck K. New horizons for cystic fibrosis treatment. Pharmacol Ther 2017; 170: 205–211. - PubMed
    1. Spoonhower KA, Davis PB. Epidemiology of cystic fibrosis. Clin Chest Med 2016; 37: 1–8. - PubMed
    1. Saint-Criq V, Gray MA. Role of CFTR in epithelial physiology. Cell Mol Life Sci 2017; 74: 93–115. - PMC - PubMed

LinkOut - more resources